Evolus

The Evolus management team will be in Miami for two major investor conferences, where they will participate in fireside chats and investor meetings, sharing insights on our #performance beauty strategy and growth plans. ? ? The Leerink Partners Global Biopharma Conference, the fireside chat will take place on Tuesday, March 11, 2025, at 9:20 AM ET.? ? ? The Barclays 27th Annual Global Healthcare Conference, the fireside chat will take place on Wednesday, March 12, 2025, at 3:30 PM ET.?? ? Join us for the fireside chats on our Investor Relations page here: https://lnkd.in/eWyZ-uJJ ? ? #Evolus #EvolveWithUs #PerformanceBeauty #MedicalAesthetics

The Evolus management team is excited to participate in the TD Cowen 2nd Annual Glowing Ahead: Beauty & Wellness Summit in New York City on February 27. As part of the event, our President and CEO David Moatazedi, will host a fireside chat from 9:30am – 10:00am ET to discuss our leadership in #performance beauty and the continued growth of Evolus. Tune in to the live webcast or catch the replay on our Investor Relations page here: https://lnkd.in/eWyZ-uJJ #Evolus #EvolveWithUs #PerformanceBeauty #MedicalAesthetics

Evolus has achieved a major milestone with FDA approval of Evolysse? Form and Evolysse? Smooth injectable hyaluronic acid (HA) gels, marking our entry into the U.S. HA dermal filler market. This technological breakthrough expands our addressable market by 78% and accelerates our transformation into a multi-product leader in #performance beauty. ? Evolysse? introduces the first major #innovation in injectable HA dermal fillers in a decade, powered by SYMATESE’s Cold-X? technology for long-lasting, natural-looking results. Launching in Q2 2025, these products will seamlessly integrate with our fast-growing neurotoxin business, leveraging our strong customer relationships, innovative co-branded marketing, and competitive brand positioning. ? With a high overlap between the customer and consumer base for neurotoxins and fillers, Evolysse? is perfectly positioned to drive significant value. Supported by one of the most extensive clinical trial programs in HA filler history, Evolysse? products are being evaluated for safety and effectiveness in over 2,000 patients globally. This is just the beginning – we look forward to expanding the Evolysse? collection with Evolysse? Sculpt in 2026 and Evolysse? Lips in 2027! Read the full press release: https://lnkd.in/eJctksm8 ? #Evolus #EvolveWithUs #PerformanceBeauty #MedicalAesthetics?

IMCAS 2025 was even bigger and busier than ever before. More than 20,000 attendees from around the world converged on Paris last weekend demonstrating the interest and growth in this buoyant sector.? ? Evolus CEO David Moatazedi participated in a dynamic panel discussion at the IMCAS Tribune, focusing on neurotoxins and the future of the aesthetics industry. He shared insights on evolving consumer expectations and why the future lies in enhancing the #performance beauty experience, including a deep dive into Evolus’ innovative products, such as Evolysse? and Estyme?. ? David was joined in Paris by Dr. Rui Avelar, MD, our CMO and Head of R&D, who presented a paper on the next generation of injectable hyaluronic acid gels.?Evolysse? represents the first major technological breakthrough in HA?dermal fillers in a decade, raising the standard for performance. These injectable HA gels are currently in the late stages of the U.S. regulatory approval process, with plans, upon approval, for a launch starting in Q2 2025. ? #Evolus #IMCAS2025 #PerformanceBeauty #MedicalAesthetics

Evolus CEO David Moatazedi recently joined Oliver Renick on the Schwab Network to discuss our continued growth and the exciting road ahead. We have captured 13% market share with Jeuveau?, the fastest-growing neurotoxin in the U.S. for four consecutive years and are preparing to expand our portfolio with the upcoming launch of Evolysse?, our line of unique injectable hyaluronic acid (HA) gels. ? Evolysse? represents the first breakthrough technological #innovation in the HA filler market in over a decade and is being evaluated in over 2,000 patients globally. With FDA approval expected in the next 90 days and a planned launch in Q2 2025, we are excited to bring this highly differentiated Cold-X? technology to the cash-pay aesthetics market, strengthening our leadership in #performance beauty. ? As a company that has delivered over 30% revenue growth for five years, we are well-positioned to build on this momentum. With a strong foundation in place and a growing portfolio, we look forward to continuing to redefine aesthetics and drive long-term value for our customers and shareholders. https://lnkd.in/eZeqaSQM ? $EOLS #Evolus #EvolveWithUs #PerformanceBeauty #MedicalAesthetics

Today, we announced our preliminary fourth quarter and full-year 2024 net revenue, achieving record results at the top of guidance. We also issued 2025 guidance, highlighting our momentum heading into the new year. With expected U.S. approval within 90 days for our new product line of unique injectable hyaluronic acid (HA) gels and a clear path to full-year profitability in 2025, we are poised for another year of exceptional growth. View the press release here: https://lnkd.in/eAtkQvya $EOLS

We are deeply grateful to the brave first responders working tirelessly to keep our communities safe during the devastating wildfires in Southern California. At Evolus, the safety of our employees, partners, and the wider community is our top priority. The strength of our community is rooted in its people, and we are proud to be part of this resilient region.

We are proud to congratulate our CFO, Sandra Beaver, on receiving the Rising Star award at the 2nd annual CFO Leadership Awards, hosted by StrategicCFO360 and the The CFO Leadership Council. This distinguished honor highlights Sandra’s remarkable early career achievements, including her innovation, versatility, and strategic leadership in the finance community. Her contributions continue to propel Evolus forward, and we’re excited to celebrate this well-deserved recognition!?A special thank you to Jack McCullough, President of the CFO Leadership Council, and KimMarie Hagerty, publisher of the StrategicCFO360 channel, for presenting this prestigious award.? ? #Evolus #EvolveWithUs #PerformanceBeauty #MedicalAesthetics ? ??Credit: Ben Hider Photography

ICYMI, Evolus CEO David Moatazedi was featured in Nasdaq’s #BehindtheBell series where he discussed our leadership position in performance beauty, cash-pay model, and innovation in #aesthetics. Check out the interview: https://lnkd.in/eCxZSyvY $EOLS #Evolus #EvolveWithUs #PerformanceBeauty #MedicalAesthetics

Last week, Evolus CEO David Moatazedi, CFO Sandra Beaver, and CMO Rui Avelar, MD, joined other leaders at the Stifel Healthcare Conference in New York City to discuss our flagship toxin, expectation of our line of injectable HA gels, and outlook for 2025 and beyond. Listen to a replay of the discussion here:?https://lnkd.in/eYtd5rUb $EOLS #Evolus #EvolveWithUs #PerformanceBeauty #MedicalAesthetics